What does Arcutis Biotherapeutics do?
Arcutis Biotherapeutics, Inc. is a Nasdaq-listed commercial-stage medical dermatology company trading under ARQT. It reports one operating segment and is built around ZORYVE, a family of once-daily topical roflumilast formulations. The company’s official corporate site frames its strategy as focused innovation for immune-mediated skin disease rather than broad pharmaceutical diversification.
Who uses its products, and why does dosage form matter?
ZORYVE addresses plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Cream strengths target different diseases and ages, while foam suits scalp and hair-bearing areas. As of July 2026, cream 0.3% covers plaque psoriasis from age two; cream 0.15% covers atopic dermatitis from age six; cream 0.05% covers ages two to five; and foam 0.3% covers seborrheic dermatitis from age nine and scalp/body plaque psoriasis from age twelve.
This architecture lets Arcutis use one validated molecule across formulations, ages, body locations, and prescriber groups. Dermatologists remain central, while pediatric and primary-care channels grow with younger labels. The United States dominates: sales outside it were less than 10% of product revenue in Q1 2026 and FY2025.
| Research lens | Arcutis profile | Why it matters |
|---|---|---|
| Listing and sector | Nasdaq: ARQT; commercial-stage biopharmaceuticals | Valuation depends on commercial execution and clinical optionality rather than a pre-revenue pipeline alone. |
| Business scope | One reportable segment: development and commercialization of dermatology treatments | Financial statements provide product-level detail, but no diversified segment cushion. |
| Core customers | Dermatologists, patients, payers, specialty pharmacies, pediatric and primary-care prescribers | Prescription demand must convert through insurance coverage and gross-to-net deductions. |
| Geographic exposure | Predominantly United States, with Canada and licensed Asian territories | The U.S. reimbursement environment remains the dominant economic variable. |
How does Arcutis make money from the ZORYVE franchise?
Arcutis records ZORYVE revenue after rebates, discounts, returns, assistance, and other gross-to-net deductions. Regional partners add smaller milestone or license revenue in Japan and parts of Greater Asia. The core engine is U.S. prescription volume multiplied by realized net price. The 2025 Form 10-K shows product sales rapidly replacing licensing revenue as the principal value source.
Which formulation contributes the most revenue?
How do licensing, reimbursement, and manufacturing affect the economics?
Arcutis licensed topical dermatology rights to roflumilast from AstraZeneca in 2018, reducing discovery risk but creating low-to-high single-digit royalties and milestones. FY2025 royalty expense was $11.2 million. Third-party manufacturing keeps fixed capital modest but adds supplier and continuity risk.
| Revenue or cost layer | Mechanism | Analytical implication |
|---|---|---|
| Net product sales | Prescription volume and realized price after rebates, discounts, returns, and assistance | Demand growth is not enough; payer access and gross-to-net discipline determine reported revenue. |
| Regional licensing | Milestones and partner economics in Japan, China, and other Asian territories | Useful optionality, but smaller and less recurring than U.S. product revenue. |
| Roflumilast royalties | Low-to-high single-digit percentage owed to AstraZeneca | A durable variable cost that should remain in long-run margin assumptions. |
| Commercial infrastructure | Dermatology field force plus a targeted pediatric and primary-care build-out | Higher near-term SG&A can create operating leverage only if prescription growth scales faster. |
Which turning points built today’s commercial-stage company?
Arcutis developed through focused bets: license a validated molecule, engineer differentiated topicals, build a specialist commercial organization, and extend one franchise across diseases and ages.
-
2016
The company was formed in Delaware, establishing the focused medical-dermatology platform that still defines its scope.
-
2018
Arcutis licensed worldwide topical dermatology rights to roflumilast from AstraZeneca, creating the asset around which ZORYVE was built.
-
2020
The January initial public offering funded late-stage development and the transition toward commercial readiness.
-
2022
The first ZORYVE cream approval and launch established commercial proof; the Ducentis acquisition added the systemic candidate now called ARQ-234.
-
2023
ZORYVE foam gained approval for seborrheic dermatitis, validating the value of a formulation suited to hair-bearing areas.
-
2024
Atopic-dermatitis approval broadened the franchise, while a $100.0M debt prepayment reduced balance-sheet risk.
-
2025
Scalp-and-body psoriasis and pediatric atopic-dermatitis labels expanded the addressable population; FY2025 product revenue reached $372.1M.
-
2026
Q1 operating cash flow turned positive, plaque-psoriasis cream expanded to age two, and an infant atopic-dermatitis application entered FDA review.
The 2018 transaction supplied a validated PDE4 mechanism without requiring new-molecule discovery, letting Arcutis concentrate on formulation, trials, regulation, and commercialization. The trade-off is structural: economics include royalties, and patent defense depends heavily on formulation and method-of-use claims.
Why is 2026 an important inflection point?
The company must now prove ZORYVE can fund label expansion and ARQ-234. Positive Q1 2026 operating cash flow is encouraging, but not yet durable evidence. Label growth, payer access, and broader prescribing must outweigh added selling and pipeline costs.
What gives ZORYVE a competitive advantage?
Why do formulation and label breadth matter?
ZORYVE combines once-daily dosing, steroid-free positioning, cream and foam delivery, and three disease labels. Foam addresses scalp use, while pediatric strengths widen lifetime patient reach. The June 2026 plaque-psoriasis expansion to age two was ZORYVE’s seventh FDA approval in four years, making regulatory execution a practical capability.
The original molecule patent expired in 2020, so Arcutis relies on formulation, dosing, composition, and method claims, including Orange Book patents. These can be valuable, but generic defense is less absolute than with an unexpired molecule patent.
Which competitors pressure adoption?
| Competitive set | Examples named in filings | Pressure on Arcutis | ZORYVE response |
|---|---|---|---|
| Low-cost topical standards | Generic corticosteroids and vitamin-D combinations | Familiar, inexpensive, and widely covered | Steroid-free chronic-use positioning and once-daily convenience |
| Branded nonsteroidal topicals | VTAMA, Opzelura, and Eucrisa | Compete for formulary status and prescriber attention | Multiple indications, strengths, and cream/foam choices |
| Systemic and biologic therapies | Dupixent, Skyrizi, RINVOQ, Sotyktu, and others | May be preferred for more extensive or severe disease | Topical option with limited systemic exposure for appropriate patients |
| Future generic roflumilast | Potential challengers to formulation patents | Could compress price and erode exclusivity | Patent estate, know-how, label breadth, and installed commercial relationships |
Management calls ZORYVE the leading prescribed branded topical across its three indications, not an independently verified monopoly. Payers control access, prescribers have alternatives, and inexpensive steroids set a demanding price-value benchmark.
What does Arcutis’ latest quarter show?
The Q1 2026 earnings release shows rapid franchise growth, high product margin, and narrower losses alongside heavy commercial and development spending. Product revenue rose 65% year over year to $105.4 million but fell 17% sequentially as deductible resets and insurance changes pressured first-quarter economics.
What changed versus the prior-year quarter?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Net product revenue | $105.4M | $63.8M | Demand and improved gross-to-net deductions drove 65% growth. |
| Cost of sales | $9.8M | $8.8M | Cost grew far more slowly than revenue, supporting high product margin. |
| R&D expense | $30.6M | $17.5M | Included a $10.0M ARQ-234 milestone triggered by first-patient dosing. |
| SG&A expense | $74.1M | $64.0M | Higher personnel and commercialization spending supported broader reach. |
| Operating loss | $9.1M | $24.5M | Revenue scale narrowed the loss despite higher R&D and SG&A. |
| Net loss per share | $0.09 loss | $0.20 loss | Per-share loss more than halved year over year. |
| Operating cash flow | $2.2M | $30.4M outflow | A major improvement, although working-capital timing contributed. |
Why can gross margin be strong while the company still loses money?
Topical product cost is small relative to net price, but gross profit funds commercial infrastructure, label-expansion trials, regulation, and ARQ-234. In Q1 2026, SG&A was about 70% of product revenue and R&D about 29%. The Q1 2026 Form 10-Q supports an operating-leverage thesis, not mature profitability.
How financially strong is Arcutis?
What does the annual revenue trajectory show?
ZORYVE has become a material franchise: product revenue rose from $29.2 million in FY2023 to $166.5 million in FY2024 and $372.1 million in FY2025. As the base expands, financial strength increasingly depends on sales scaling faster than commercial and clinical costs.
How should cash flow and liquidity be interpreted?
Positive quarterly cash flow helps funding, but Q1 2026 benefited from accrued-liability and other working-capital movements. Inventory rose to $37.4 million from $22.6 million at year-end 2025, while receivables were $144.4 million. Cash conversion should be judged across several quarters.
How does capital allocation affect the story?
Capital goes to ZORYVE adoption, new roflumilast labels, and ARQ-234. A $100.0 million debt prepayment in October 2024 left $100.0 million of principal at year-end 2025; the 2029 floating-rate maturity keeps interest relevant. FY2025 stock compensation of $40.4 million is noncash but affects per-share value.
Who owns Arcutis stock, and how is it governed?
Arcutis has one common-stock class with one vote per share. No individual has permanent super-voting control; specialist funds, large institutions, directors, and executives shape governance. The 2026 proxy statement used 125,073,249 shares outstanding on April 8, 2026.
| Holder or group | Beneficial shares | Stake | Governance relevance |
|---|---|---|---|
| Suvretta Capital Management | 9,534,837 | 7.6% | Specialist institutional ownership can increase scrutiny of pipeline and commercial milestones. |
| BlackRock | 9,029,624 | 7.2% | Large passive ownership reinforces standard public-company governance expectations. |
| Frazier Life Sciences VIII | 8,785,284 | 7.0% | Longstanding life-sciences sponsorship and board relationships matter to strategic continuity. |
| Rubric Capital Management | 8,271,577 | 6.6% | Another material institutional block, but not a controlling position. |
| Directors and executive officers as a group | 11,764,645 | 9.4% | Meaningful alignment, although the figure includes overlapping affiliated holdings and exercisable awards. |
| President and CEO Frank Watanabe | 1,362,770 | 1.1% | Economic exposure aligns leadership with per-share outcomes without creating control. |
Is there a controlling shareholder?
No disclosed holder controls a voting majority. Positions should not be added mechanically because affiliated entities and director relationships overlap. Management therefore needs broad shareholder support, leaving strategy, compensation, and capital allocation subject to normal governance pressure.
What do leadership and board incentives signal?
Frank Watanabe has led Arcutis since April 2017. The July 2026 appointment of Chris Peetz added pharmaceutical scaling, transaction, and commercialization experience. Compensation combines annual goals with long-term equity; 2025 corporate-goal achievement was 125% of target. Researchers should still test whether incentives reward durable cash returns and per-share discipline.
Pipeline expansion and reimbursement will decide the next growth phase
Arcutis must widen eligible populations, win payer access, reach new prescribers efficiently, and create assets beyond approved labels. Its official pipeline combines near-market roflumilast extensions with earlier clinical optionality.
Which catalysts are closest to commercial value?
The July 2026 FDA acceptance of the infant application could extend ZORYVE into the earliest age cohort. Vitiligo and hidradenitis suppurativa remain probability-weighted opportunities, not embedded revenue.
How can commercial reach expand without destroying operating leverage?
Arcutis expanded its dermatology sales force in May 2026, began a pediatric and primary-care team, and launched a virtual-health access platform in June. These initiatives can expand demand but raise fixed commercial costs before the benefit is fully visible.
What risks could change the Arcutis outlook?
Focus also creates vulnerability. Nearly all commercial value comes from one active ingredient and brand family, so reimbursement, safety, patent, supply, or competitive setbacks could affect several indications at once.
Which filing risks are most financially material?
Management must spend ahead of revenue, but excessive investment delays durable profitability. The $10.0 million Q1 2026 ARQ-234 milestone raised R&D because the program advanced, not because ZORYVE weakened. Analysts should separate productive milestones from structural inefficiency.
Why does Arcutis matter for a DCF valuation?
Arcutis sits between valuation regimes: it is no longer pre-revenue, yet lacks mature margins and predictable free cash flow. A credible DCF separates approved ZORYVE economics from pipeline optionality and does not extrapolate one working-capital-influenced quarter.
| DCF driver | Company-specific anchor | Modeling treatment |
|---|---|---|
| Approved-product revenue | FY2026 guidance of $480M–$495M | Build by formulation, indication, age expansion, volume, and realized net price. |
| Product gross margin | Approximately 90.7% in Q1 2026 on an implied product basis | Retain royalties, manufacturing costs, and gross-to-net sensitivity rather than assuming a fixed peak margin. |
| Operating leverage | Q1 2026 SG&A of $74.1M and R&D of $30.6M | Model when expense growth falls below revenue growth, not merely when gross profit rises. |
| R&D normalization | Q1 2026 included a $10.0M ARQ-234 milestone | Separate recurring trial spend from lumpy contractual milestones. |
| Cash conversion | Q1 2026 operating cash flow of $2.2M | Normalize receivables, inventory, accrued liabilities, and stock-based compensation over several periods. |
| Terminal value and exclusivity | Key formulation patents generally extend to 2037 or later | Use indication-specific erosion assumptions and a cautious terminal period rather than perpetual peak economics. |
| Per-share bridge | Cash and securities exceed debt, but equity awards remain material | Subtract debt, add excess cash, and include options, restricted awards, and other dilution in the share count. |
What should the model normalize?
Normalize first-quarter insurance seasonality, separate product gross margin from corporate margin, and model milestones, launch spending, and working capital explicitly. Treat stock compensation as a per-share cost despite its noncash cash-flow treatment, and include the 2029 floating-rate debt maturity.
Where should pipeline optionality sit?
This structure avoids giving full value to unproven indications or no value to a demonstrated platform. The appropriate output is a scenario range, not a recommendation or falsely precise target.
What is the key takeaway from Arcutis analysis?
Arcutis converted a licensed molecule into a fast-growing, high-gross-margin dermatology franchise. Each label can expand opportunity without a wholly new infrastructure. Concentration remains the weakness: ZORYVE must preserve access, patents, supply, and prescriber preference while funding commercialization and pipeline work.
Arcutis is a case study in focused differentiation, buyer power, regulatory execution, and operating leverage. In valuation, the approved franchise should carry the analytical burden; pipeline value is probability-weighted, while patent, reimbursement, dilution, and cash-conversion risks stay explicit.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.